Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

378 17 Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
specific, major histocompatibility complex-restricted
specificity of T cells. Proc
Natl Acad Sci USA 93: 1820±4.
171 Reiter Y, Di Carlo A, Fugger L, Engberg
J, Pastan I (1997) Peptide-specific
killing of antigen-presenting cells by a
recombinant antibody±toxin fusion protein
targeted to major histocompatibility
complex/peptide class I complexes
with T cell receptor-like specificity. Proc
Natl Acad Sci USA 94: 4631±6.
172 Engberg J, Krogsgaard M, Fugger L
(1999) Recombinant antibodies with
the antigen-specific, MHC restricted
specificity of T cells: novel reagents for
basic and clinical investigations and immunotherapy.
Immunotechnology 4:
273±8.
173 de Haard HJ, van Neer N, Reurs A,
et al. (1999) A large non-immunized
human Fab fragment phage library that
permits rapid isolation and kinetic analysis
of high affinity antibodies. J Biol
Chem 274: 18218±30.
174 Chames P, Hufton SE, Coulie PG,
Uchanska-Ziegler B, Hoogenboom
HR (2000) Direct selection of a human
antibody fragment directed against the
tumor T-cell epitope HLA-A1±MAGE-
A1 from a nonimmunized phage-Fab
library. Proc Natl Acad Sci USA 97:
7969±74.
175 Gram H, Marconi LA, Barbas CF III,
Collet TA, Lerner RA, Kang AS
(1992) In vitro selection and affinity
maturation of antibodies from a naive
combinatorial immunoglobulin library.
Proc Natl Acad Sci USA 89: 3576±80.
176 Crameri A, Cwirla S, Stemmer WP
(1996) Construction and evolution of
antibody-phage libraries by DNA shuffling.
Nat Med 2: 100±2.
177 Chowdhury PS, Pastan I (1999) Improving
antibody affinity by mimicking
somatic hypermutation in vitro. Nat
Biotechnol 17: 568±72.
178 Beers R, Chowdhury P, Bigner D,
Pastan I (2000) Immunotoxins with increased
activity against epidermal
growth factor receptor vIII-expressing
cells produced by antibody phage display.
Clin Cancer Res 6: 2835±43.
179 Pai LH, Pastan I (1998) Clinical trials
with Pseudomonas exotoxin immunotox-
ins. Curr Topics Microbiol Immunol 234:
83±96.
180 Siegall CB, Liggitt D, Chace D, Tepper
MA, Fell HP (1994) Prevention of
immunotoxin-mediated vascular leak
syndrome in rats with retention of antitumor
activity. Proc Natl Acad Sci USA
91: 9514±8.
181 Siegall CB, Liggi11 D, Chace D,
Mixan B, Sugai J, Davidson T, S1 einitz
M (1997) Characterization of vascular
leak syndrome induced by the
toxin component of Pseudomonas exotoxin-based
immunotoxins and its potential
inhibition with nonsteroidal
anti-inflammatory drugs. Clin Cancer
Res 3: 339±45.
182 McLaughlin P, Grillo-Lopez AJ,
Link BK, et al. (1998) Rituximab chimeric
anti-CD20 monoclonal antibody
therapy for relapsed indolent lymphoma:
half of patients respond to a
four-dose treatment program. J Clin
Onco1 16: 2825±33.
183 Baluna R,Vitetta ES (1997) Vascular
leak syndrome: a side effect of immunotherapy.
Immunopharmacology 37:
117±32.
184 Kuan C, Pai LH, Pastan I (1995) Immunotoxins
containing Pseudomonas
exotoxin targeting Ley damage human
endothelial cells in an antibody-specific
mode: relevance to vascular leak syndrome.
Clin Cancer Res 1: 1589±94.
185 Rozemuller H, Rombouts WJC,
Touw IP, et al. (1996) Treatment of
acute myelocytic leukemia with interleukin-6
Pseudomonas exotoxin fusion
protein in a rat leukemia model. Leukemia
10: 1796±803.
186 Lindstrom AL, Erlandsen SL, Kersey
JH, Pennell CA (1997) An in vitro
model for toxin-mediated vascular leak
syndrome: ricin toxin A chain increases
the permeability of human endothelial
cell monolayers. Blood 90: 2323±34.
187 Baluna R,Vitetta ES (1999) An in vivo
model to study immunotoxin-induced
vascular leak in human tissue. JImmunother
22: 41±47.
188 Baluna R, Rizo J, Gordon BE,
Ghetie V, Vitetta ES (1999) Evidence
for a structural motif in toxins and interleukin-2
that may be responsible for